SkinJect Information

Skinject, Inc. is developing a novel drug delivery system for the treatment of non-melanoma skin cancers. The system comprises a dissolvable microneedle array (MNA) to deliver a drug directly into the top layer of skin. The drug will kill non-melanoma skin cancer by causing an immune system reaction to combat the disease. SkinJect consists of three key components: - Dissolvable microneedles that penetrate the skin, dissolve and deliver the “cargo” − the drug. - A cellulose-like material that forms the microneedles and carries the cargo. It is FDA-approved for human use. - A chemotherapy cargo that kills cells and also stimulates an immunological response from the patient’s lesion. Also FDA-approved for human use.